Regeneron Pharmaceuticals, Inc. (FRA:RGO)

Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	17,528	2,488	2,730	3,106	2,886	2,194
Short-Term Investments	-	6,524	8,115	4,636	2,809	1,393
Cash & Short-Term Investments	17,528	9,013	10,845	7,742	5,695	3,587
Cash Growth	78.69%	-16.90%	40.07%	35.96%	58.76%	11.59%
Accounts Receivable	5,610	5,844	5,299	5,023	5,059	3,112
Other Receivables	-	367.8	368.5	305.6	977.5	1,003
Receivables	5,610	6,212	5,667	5,329	6,037	4,115
Inventory	3,206	3,087	2,581	2,402	1,951	1,917
Prepaid Expenses	-	348.4	386.6	411.2	332.4	160.8
Restricted Cash	-	0.8	-	-	-	-
Total Current Assets	26,343	18,661	19,479	15,884	14,015	9,779
Property, Plant & Equipment	4,841	4,817	4,224	3,834	3,482	3,222
Long-Term Investments	-	9,060	5,471	6,640	6,878	3,195
Other Intangible Assets	1,352	1,149	1,039	915.5	6.7	-
Long-Term Deferred Tax Assets	3,572	3,314	2,575	1,724	876.9	858.9
Other Long-Term Assets	2,111	758.8	291.8	216.9	176.1	108.9
Total Assets	38,219	37,759	33,080	29,215	25,435	17,163
Accounts Payable	4,887	789.5	606.6	589.2	564	475.5
Accrued Expenses	-	2,497	2,339	2,054	1,593	1,609
Current Portion of Leases	-	30.3	19	12.4	719.7	-
Current Income Taxes Payable	-	-	-	-	326.3	19.5
Current Unearned Revenue	-	627.7	458.9	485.3	442	577.7
Other Current Liabilities	-	-	-	-	287.4	16.1
Total Current Liabilities	4,887	3,944	3,423	3,141	3,933	2,697
Long-Term Debt	1,985	1,984	1,983	1,981	1,980	1,979
Long-Term Leases	720	924.1	788.7	775.8	-	717.2
Long-Term Unearned Revenue	688.2	185.7	126.7	69.8	73.3	57.8
Other Long-Term Liabilities	-	1,367	785.4	582.2	680.2	687.1
Total Liabilities	8,280	8,406	7,107	6,551	6,666	6,138
Common Stock	29,939	0.1	0.1	0.1	0.1	0.1
Additional Paid-In Capital	-	12,856	11,354	9,949	8,088	6,716
Retained Earnings	-	31,673	27,260	23,307	18,968	10,893
Treasury Stock	-	-15,167	-12,560	-10,353	-8,261	-6,613
Comprehensive Income & Other	-	-7.9	-80.9	-238.8	-26.2	29.3
Shareholders' Equity	29,939	29,354	25,973	22,664	18,769	11,025
Total Liabilities & Equity	38,219	37,759	33,080	29,215	25,435	17,163
Total Debt	2,705	2,939	2,791	2,770	2,700	2,696
Net Cash (Debt)	14,823	14,974	13,451	11,565	9,833	4,027
Net Cash Growth	-0.03%	11.32%	16.31%	17.61%	144.18%	-30.05%
Net Cash Per Share	131.87	130.09	118.30	101.89	87.64	34.99
Filing Date Shares Outstanding	105.1	107.02	107.46	106.73	106.44	104.14
Total Common Shares Outstanding	105.1	107.3	107.12	107	106.57	103.96
Working Capital	21,456	14,717	16,056	12,743	10,082	7,082
Book Value Per Share	284.86	273.57	242.47	211.81	176.11	106.05
Tangible Book Value	28,587	28,205	24,935	21,749	18,762	11,025
Tangible Book Value Per Share	272.00	262.86	232.78	203.26	176.05	106.05
Land	-	288.2	283.1	264.5	248	241.2
Buildings	-	2,573	2,423	2,270	2,089	1,891
Machinery	-	2,149	1,940	1,803	1,662	1,395
Construction In Progress	-	1,722	1,345	980.5	767.7	724.5
Leasehold Improvements	-	154.5	133.9	114.3	113.9	100.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.